We are live on
!
Find out more
CC
Caxton Corporation Portfolio holdings
AUM
$4.02M
1-Year Est. Return
256.08%
This Fund
S&P 500
This Quarter
Est. Return
+29.36%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$17.6M
AUM Growth
-$973K
(-5.3%)
Cap. Flow
-$2.53M
Cap. Flow
% of AUM
-14.42%
Top 10 Holdings %
Top 10 Hldgs %
99.77%
Holding
15
New
3
Increased
1
Reduced
3
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kyverna Therapeutics
KYTX
|
+$442K |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$266K |
| 3 |
DFTX
Definium Therapeutics
DFTX
|
+$166K |
| 4 |
Adicet Bio
ACET
|
+$45.2K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Savara
SVRA
|
+$1.66M |
| 2 |
Xeris Biopharma Holdings
XERS
|
+$1.37M |
| 3 |
Apogee Therapeutics
APGE
|
+$205K |
| 4 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
+$129K |
| 5 |
ALLK
Allakos
ALLK
|
+$67.5K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.03% |
| 2 | Financials | 2.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Xeris Biopharma Holdings
XERS
$1.52B
| $11.3M | 64.38% |
5,113,348
-528,572
| -9% | -$1.37M |
|
2
Rezolute
RZLT
$444M
| $3.36M | 19.16% |
1,318,967
| – | – |
|
|
3
State Street SPDR S&P 500 ETF Trust
SPY
$774B
| $971K | 5.53% |
1,856
+534
| +40% | +$266K |
|
4
Berkshire Hathaway Class B
BRK.B
$1.06T
| $428K | 2.44% |
1,019
-16
| -2% | -$6.29K |
|
|
5
Kyverna Therapeutics
KYTX
$453M
| $394K | 2.24% |
+15,846
| New | +$442K |
|
|
MTEM
6
DELISTED
Molecular Templates, Inc.
MTEM
| $307K | 1.75% |
136,866
| – | – |
|
|
DFTX
7
Definium Therapeutics
DFTX
$5.88B
| $273K | 1.56% |
+29,065
| New | +$166K |
|
|
ABVX
8
Abivax
ABVX
$11.9B
| $226K | 1.29% |
15,808
-935
| -6% | -$12.1K |
|
9
Lexeo Therapeutics
LXEO
$368M
| $162K | 0.92% |
10,319
| – | – |
|
10
Compass Therapeutics
CMPX
$369M
| $86.1K | 0.49% |
43,465
| – | – |
|
|
11
Adicet Bio
ACET
$75.9M
| $41.1K | 0.23% |
+1,093
| New | +$45.2K |
|
|
ALLK
12
DELISTED
Allakos
ALLK
| – | – |
-24,710
| Closed | -$67.5K |
|
|
13
Apogee Therapeutics
APGE
$10.1B
| – | – |
-7,353
| Closed | -$205K |
|
|
14
Savara
SVRA
$1.13B
| – | – |
-353,441
| Closed | -$1.66M |
|
|
HARP
15
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| – | – |
-13,176
| Closed | -$129K |
|
Similar funds
PCM
EAMS
RCP
RA
CGA
HFA
ABA
UOMF
Caxton Corporation's Q1 2024 Portfolio in Review
As of Q1 2024, Caxton Corporation held 15 positions worth $17.6M, down 5.3% from $18.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Caxton Corporation withdrew a net $2.53M in Q1 2024, closing 4 positions and reducing 3 holdings. Its most notable exit was Savara, an estimated $1.66M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Financials.
Against the trend, Caxton Corporation opened a new position in Kyverna Therapeutics worth $394K.
- Caxton Corporation's largest Q1 2024 buy was Kyverna Therapeutics: 15,846 shares worth $394K.
- Caxton Corporation added most to State Street SPDR S&P 500 ETF Trust in Q1 2024, an estimated $266K increase.
- Caxton Corporation's biggest Q1 2024 reduction was Xeris Biopharma Holdings, cutting an estimated $1.37M.
- Caxton Corporation fully exited Savara in Q1 2024, selling an estimated $1.66M.
- Caxton Corporation's ten largest holdings make up 100% of its $17.6M portfolio in Q1 2024.
- Caxton Corporation opened 3 new positions and closed 4 in Q1 2024.
- Caxton Corporation's portfolio value fell 5.3% quarter-over-quarter to $17.6M.
Based on Caxton Corporation's 13F filing for Q1 2024, filed 15 May 2024.